{
    "nctId": "NCT02067637",
    "briefTitle": "Delayed Effects of Treatment in Cancer Survivors (DETECS)",
    "officialTitle": "Delayed Effects of Treatment in Cancer Survivors (DETECS)",
    "overallStatus": "WITHDRAWN",
    "conditions": "Breast Cancer, Leukemia, Lymphoma, Gynecologic Cancer",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 0,
    "primaryOutcomeMeasure": "Serum anti-Mullerian hormone (AMH)",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Exposed: Females between the ages of 18 and 45, at least 2 years from the completion of cancer therapy. Subjects will have one of the following cancer diagnoses: breast, leukemia, lymphoma, and/or any gynecologic cancer. Subjects must also be postmenarchal, have a uterus, at least one intact ovary, and must be willing and able to comply with study procedures. Subjects can be of any menopausal status and within 10 years post treatment.\n* Unexposed: Females between the ages of 18 and 45 with no prior history of cancer treatment.\n\nExclusion Criteria:\n\n* Exposed: Pregnancy, lactation within the previous 3 months, any medical condition other than cancer with a known correlation with premature menopause (i.e. Turner's syndrome, Fragile X, gonadal dysgenesis, polyglandular autoimmune syndrome, lupus, etc.), hormonal contraceptive use within 3 months.\n* Unexposed: Healthy controls with a history of polycystic ovary syndrome (PCOS), diabetes, thyroid dysfunction, hypertension, and hypercholesterolemia will be excluded in addition to cancer patients or survivors with one of the aforementioned diseases diagnosed prior to cancer diagnosis or treatment.",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT"
}